The new double GIP/GLP-1 is a used primarily to treat type 2 diabetes. It is composed of fragments of two hormones, GIP (glucagon-like peptide) and GLP-1 (glucagon-like peptide -1). GIP and GLP-1 are peptide hormones produced in the pancreas that promote insulin secretion, lower blood sugar levels, reduce gastrointestinal motility, and delay gastric emptying.

This new dual GIP/GLP-1 has the following features:
1. Double pharmacological effects: it can activate the receptors of GIP and GLP-1 at the same time, enhance the secretion of insulin and inhibit the release of glucagon, thereby reducing blood sugar levels more effectively.
2. Long-term effect: due to the change of the nature of GIP and GLP-1 itself easily degraded by enzymes, this dual drug has a longer half-life, making its effect more lasting.
3. Reduce weight: The drug can suppress appetite and reduce intake, thereby helping to reduce weight.

preparation method, the current research mainly through the synthesis technology to prepare double GIP/GLP-1. The preparation process is complicated, and it is necessary to modify and connect the fragments of GIP and GLP-1 in order to improve the stability and efficacy.

Regarding safety information, this drug is currently in the research phase and is not yet on the market. Although there is no clear data on toxic side effects, the side effects observed in the study include nausea, vomiting, diarrhea and other digestive system reactions. In addition, for patients who are allergic to GLP-1 receptors, there may be a risk of allergic reactions.

It is important to note that the use of any drug should be carried out under the guidance of a doctor and follow the appropriate dosage and usage. If there is any discomfort or unclear situation, please consult a doctor in time.